X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Aligned Pathway

    UK Grants Pharma Firms Early Access to Aligned Pathway

    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Aligned Pathway

    UK Grants Pharma Firms Early Access to Aligned Pathway

    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

Personalised medicines, intelligent packaging and FDA deadlines seen as major trends for pharma packaging in 2018

Content Team by Content Team
8th March 2018
in FDA Approvals, Press Statements

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Pharmapack Europe (#pharmapackeu) – organised by UBM – closed its most exciting edition to date, taking place at Paris Expo, Porte De Versailles on 7 and 8 February 2018.

Europe’s biggest pharma packaging and drug delivery exhibition and conference highlighted upcoming trends in the industry with experts delivering an in-depth media debate focussing on smart and intelligent packaging, the increasing role that the internet has on the industry, and the potential implications of upcoming regulatory changes.

As personalised medicines become more and more prominent in today’s industry, Professor Phillipe Arnaud – Chief of Pharmacy Department at Bichat-Claude Bernard Hospital and ANSM Expert – believes that customer feedback will be at the forefront of pharma packaging in the future. He envisages that with social media sites patients can write feedback to companies about certain aspects of the packaging or device that they may not like. Companies can then utilise this raw data, which can lead to a quicker evolution of new packaging with the opinion of the patients in mind.

In contrast to this, Dr. Pascale Gauthier – from the Biopharmaceutical department of the Pharmacy faculty at Auvergne University – argued that although the internet can bring benefits, it will raise problems, such as those with counterfeiting. Many people are so busy that they may not have time to see a doctor and so they are increasingly looking to the internet for their medicine ­– however most of the time these are counterfeited products, something which may become an increasing problem in 2018.

With the impending FDM/DSCSA deadlines in mind, Mr Lionel Jeannin – Global Device & Packaging Development at Novartis Pharma AG – commented that the potential impacts on manufacturing lines are vast, as companies must adapt their processes to the changes. It is a huge programme to put in place and he imagines there will be a scramble for last minute changes in the latter half of the year as companies that haven’t put plans in place for the deadlines are looking to catch up. He adds that he doesn’t foresee the impending deadlines significantly impeding the drugs supply pipeline.

All of the judges agreed that there was a need for information on drugs – such as leaflets – to become more accessible to patients. They suggested there are technologies available to do this, highlighting that intelligent packaging was likely to see a lot of investment in the coming years. However, they also said that the industry shouldn’t rush into implementing these technologies as some therapies may raise questions of overstepping the boundaries of privacy – such as doctors tracking drugs to see if patients have taken their recommended dosage.

The 2018 conference agenda enabled attendees to stay up-to-date with the latest trends and developments in the industry, comprising of four in-depth sessions. The ‘Regulatory Changes and Impacts’ session looked at tamper verification guidelines, international legislation for child resistant packaging (CRP) and sterile packaging. A keynote discussion explored the effects biological combination products are having on device development during the ‘Challenges in Packaging & Devices Development’ session.

The conference also explored the how ‘Newer Drug Delivery Devices Will Revolutionise Patient Life and Improve Treatment Adherence’ looking specifically at needle free injections, nasal delivery and patient centric packaging. But with more biotech and start-up companies creating a new wave of innovations the ‘Call For Challenges and Start-Ups’ session reviewed scale-up challenges and the current start-up ecosystem.

Finally, the Innovation Gallery returned to Pharmapack to showcase 23 of the exhibitors’ most exciting innovations, with the Pharmapack Start-Up Hub featuring a new and exciting addition: the ‘Start-Up Pitch’. This provided entrepreneurial companies with an opportunity to pitch their innovative ideas to a panel of judges, each being allocated a 5-minute time slot. Putting emphasis on the wider trends observed at the event, some of the products featured included: Saralon, printed electronics for smart packing in order to combat counterfeiting; Linguanomics RD, an IT& IoT company with a digital medical label that allows patients to get information of a product on their smartphone; and Veratrak, a cloud enterprise that secures the pharma supply chain using blockchain technology.

Anne Schumacher, Brand Director at Pharmapack Europe commented,“This year’s edition of Pharmapack has been very exciting, with the event continuing to inspire innovation throughout the industry. But it also showed what a great year there is potentially ahead, pushing on with new innovations and products. Pharmapack is now the vital conduit for executives looking for new partners, to access comprehensive information on the latest trends and do the deals driving forward pharmaceutical packaging and drug delivery.”

About UBM
UBM is the largest pure-play B2B Events organizer in the world. Our 3,750+ people, based in more than 20 countries, serve more than 50 different sectors. Our deep knowledge and passion for these sectors allow us to create valuable experiences which enable our customers to succeed. Please visit www.ubm.com

Previous Post

Alexon pharmaceuticals brings updates on its FY18 Earnings Guidance

Next Post

Sanofi may ask U.S. Approval for its drug Dengvaxia

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
Breast Cancer Therapy
Clinical Trials

US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

27th September 2025
Cerebral Folate Deficiency
Drug Development

US FDA to Approve Leucovorin for Cerebral Folate Deficiency

25th September 2025
Pediatric Eczema
Drug Development

FDA Grant Approval for Opzelura Cream for Pediatric Eczema

20th September 2025
Next Post

Sanofi may ask U.S. Approval for its drug Dengvaxia

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In